Mucormycosis is a serious infection and needs to be diagnosed intime and undergo remedial process as early as possible. The most commonly used clinical antifungals include  amphotericin B, posaconazole, or isavuconazole. These medicines are either IV (amphotericin B, posaconazole, isavuconazole) or oral  (posaconazole, isavuconazole). Other medicines, including fluconazole, voriconazole, and echinocandins, are less effective  for treating mucormycosis. Often, mucormycosis requires surgery to cut away the infected tissues if antibiotic treatment gets delayed. Efforts are also required to prevent this not at personal level but also at in-animate carrier levels.

Key learning objectives:

1. From clinical perspectives, the patient’s specimen collection should be soothing and easy. Once sample is collected it has to be put into transport media which will preserve Mucormycosis fungi intact and curb growth of unwanted bacteria in the collected specimen.

2. There is a need for selective and rich fungal media to support rapid and specific growth of causative fungi in an axenic way.

3.  The same media can be used further for rapid antifungal susceptibility testing. So within 48-50 hours clinician will have pure causative fungi and its antifungal profile in hand.

4.  This will speed-up the recovery of the patient.   

5.  This will speed up the exact line of therapy.

6.  The current general purpose fungal media are not of much use in this case.

7.  These un-met needs should surface  in the webinar.